Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

Simpson, Eric LEric LSimpsonPapp, Kim AKim APappBlauvelt, AndrewAndrewBlauveltCHIA-YU CHUHong, H Chih-HoH Chih-HoHongKatoh, NoritoNoritoKatohet al.,et al.2022-09-202022-09-2020222168-6068https://scholars.lib.ntu.edu.tw/handle/123456789/621179Primary results from the Measure Up 1 and Measure Up 2 studies demonstrated upadacitinib efficacy and safety through 16 weeks in patients with atopic dermatitis. Longer-term outcomes remain unknown.enPLACEBO[SDGs]SDG3Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trialsjournal article10.1001/jamadermatol.2022.0029352626462-s2.0-85126523347WOS:000767491100002https://scholars.lib.ntu.edu.tw/handle/123456789/604279